Search hospitals > Connecticut > New Haven
Connecticut Mental Health Center
Claim this profileNew Haven, Connecticut 06519
Global Leader in Schizophrenia
Global Leader in Psychosis
Conducts research for Cocaine Use Disorder
Conducts research for Cocaine Dependence
Conducts research for Schizoaffective Disorder
65 reported clinical trials
8 medical researchers
Summary
Connecticut Mental Health Center is a medical facility located in New Haven, Connecticut. This center is recognized for care of Schizophrenia, Psychosis, Cocaine Use Disorder, Cocaine Dependence, Schizoaffective Disorder and other specialties. Connecticut Mental Health Center is involved with conducting 65 clinical trials across 67 conditions. There are 8 research doctors associated with this hospital, such as Mohini Ranganathan, MD, Deepak C. D'Souza, M.D., Rajiv Radhakrishnan, MD, and Anahita Bassir Nia, MD.Top PIs
Mohini Ranganathan, MDConnecticut Mental Health Center3 years of reported clinical research
Studies Healthy Subjects
Studies Cannabis
8 reported clinical trials
11 drugs studied
Deepak C. D'Souza, M.D.Biological Studies Unit, VA Connecticut Healthcare System3 years of reported clinical research
Studies Alcoholism
Studies Cannabis
8 reported clinical trials
11 drugs studied
Rajiv Radhakrishnan, MDConnecticut Mental Health Center3 years of reported clinical research
Studies Healthy Subjects
Studies Cannabidiol
3 reported clinical trials
4 drugs studied
Anahita Bassir Nia, MDConnecticut Mental Health Center1 year of reported clinical research
Studies Alcohol Consumption
Studies Alcohol Use Disorder
2 reported clinical trials
2 drugs studied
Clinical Trials running at Connecticut Mental Health Center
Schizophrenia
Psychosis
HIV/AIDS
Smoking/Cigarette Smoking
Nicotine Addiction
Electronic Cigarette Use
Gender Differences
Tobacco Use Disorder
Substance Use Disorders
Cannabis
Long-term Safety of Iclepertin
for Schizophrenia
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.
Recruiting2 awards Phase 35 criteria
Iclepertin
for Schizophrenia
This trial tests if a daily pill called Iclepertin can improve learning and memory in adults with schizophrenia. Participants take either Iclepertin or another pill for several months while continuing their usual medication. Doctors regularly check their mental abilities and overall health.
Recruiting1 award Phase 318 criteria
BXCL501
for Schizophrenia Agitation
Agitation is characterized by excessive motor or verbal activity, irritability, uncooperativeness, threatening gestures, and, in some cases, aggressive or violent behavior. While agitation may have various underlying causes, patients with schizophrenia are especially vulnerable to acute episodes of agitation, especially during exacerbation of disease, and clinicians do not always diagnose these episodes early enough. Agitation associated with psychosis is a frequent reason for emergency department visits, and unless it is recognized early and managed effectively, it can rapidly escalate to potentially dangerous behaviors, including physical violence. Educating psychiatric professionals about the timely and accurate diagnosis of agitation among patients with schizophrenia or bipolar disorder and developing a well-tolerated easily administered medication will contribute to the prompt and effective management of this condition and could help reduce the risk of violent behavior and other undesirable outcomes. This study is designed to identify the ideal dose range and tolerability of sublingual Dexmedetomidine in patients with schizophrenia.
Recruiting0 awards Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Connecticut Mental Health Center?
Connecticut Mental Health Center is a medical facility located in New Haven, Connecticut. This center is recognized for care of Schizophrenia, Psychosis, Cocaine Use Disorder, Cocaine Dependence, Schizoaffective Disorder and other specialties. Connecticut Mental Health Center is involved with conducting 65 clinical trials across 67 conditions. There are 8 research doctors associated with this hospital, such as Mohini Ranganathan, MD, Deepak C. D'Souza, M.D., Rajiv Radhakrishnan, MD, and Anahita Bassir Nia, MD.